A randomized, placebo-controlled, double-blind, single-ascending-dose, Phase 1a/b study to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous NTR-641 in healthy adults and patients with acute ischemic stroke

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512196-12-00

Acronym

NTR641-01

Enrollment

Registered

2024-12-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria

None listed

Source: EU CTIS · Data processed: Feb 4, 2026